Universal Ibogaine Advises of Filing Application for Management Cease Trade Order

(TheNewswire)

Calgary, AB – TheNewswire - November 25, 2025 – Universal Ibogaine Inc.( TSXV:IBO ) (“ UI ” or the “ Company ”), a life sciences company with amission to deliver medicalized ibogaine-centered addiction care,advises that it has made an application to the Alberta SecuritiesCommission (as Principal Regulator) and the British ColumbiaSecurities Commission, to approve a temporary management case tradeorder (“ MCTO ”) under National Policy 12-203 - Cease Trade Orders for ContinuousDisclosure Defaults (“ NP 12-203 ”), which,if granted, will prohibit trading securities of the Company by theChief Executive Officer and Chief Financial Officer (positioncurrently vacant) of the Company until such time as the RequiredFilings (defined below) and all continuous disclosure requirementshave been filed by the Company, and the MCTO has been lifted.  Duringthe period in which the MCTO is in effect, the general public willcontinue to be able to trade in the Company’s listed common shares. The MCTO application has been made but there is no guarantee orassurance that the MCTO will be granted.

The Company will beunable to file its audited consolidated financial statements for thefinancial year ended July 31, 2025 (the “ Financial Statements ”) and the related management’s discussion and analysis(the “ MD&A ”) and Chief Executive Officer and Chief Financial Officercertificates for this period (collectively, with the FinancialStatements, the “ RequiredFilings ”) before the filing deadline ofNovember 28, 2025 (the “ Filing Deadline ”).

The delay in the Required Annual Filings is the resultof the Company currently having limited financial resources tocomplete the audit of the Financial Statements.  The Company expectsto rectify this situation in the near term and be in a position tocomplete the Required Filings by the end of January, 2026.  The MCTO,if granted, will be in effect until the Required Filings arecompleted.

Until the Company completes the Required AnnualFilings, the Company will comply with the alternative informationguidelines set out in NP 12-203 for issuers who have failed to complywith a specified continuous disclosure requirement within thetimelines prescribed by applicable Canadian securities laws. Theguidelines, among other things, require the Company to issue bi-weeklydefault status reports by way of a news release so long as theRequired Filings have not been filed.

About UniversalIbogaine Inc.

UI is a life sciences company, with a mission totransform addiction treatment using medicalized ibogaine through aplanned Canadian clinical trial focused on opioid use disorder, andultimately to utilize that treatment protocol globally through plannedfuture licensing agreements.

NEITHER THE TSXVENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM ISDEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTSRESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THISRELEASE.

CAUTIONARY STATEMENTREGARDING FORWARD-LOOKING STATEMENTS

?This news release may containforward-looking statements and information. Forward-lookinginformation is frequently characterized by words such ?as"plans", “planned”, "expect","project", "intends", “intended”"will", "believe", "anticipate","estimate", "scheduled",??"potential", or other similar words, or statementsthat certain events or conditions "may", "should"or ??"could" occur.  The forward-looking statements andinformation are based on certain key expectations ?and assumptionsmade by UI at the date the statements are made.  Although UI believesthat the expectations and assumptions on which the forward-?lookingstatements are based are reasonable, undue reliance should not beplaced on the forward-?looking statements because UI can give noassurance that they will prove to be correct.

Since ?forward-looking statementsaddress future events and conditions, by their very nature theyinvolve ?inherent risks and uncertainties. Actual results coulddiffer materially from those currently anticipated ?due to a number of factors andrisks, which include, but are not limited to, risks that required?regulatory approvals are not obtained. The reader is cautioned thatassumptions used in the ?preparation of such information, althoughconsidered reasonable by UI at the time of ?preparation, may proveto be incorrect and readers are cautioned not to place undue relianceon ?forward-looking information, which speaks only to conditions asof the date hereof.  UI does not ?undertake any obligation torelease publicly any revisions to forward-looking informationcontained ?herein to reflect events or circumstances that occurafter the date hereof or to reflect the occurrence ?of unanticipatedevents, except as may be required under applicable securities laws.?

Additional information identifying risks anduncertainties that could affect financial results and the Company iscontained in the Company’s filings with Canadian securitiesregulators, which are available at www.sedar.com

For furtherinformation:

Nick Karos, CEO

Universal Ibogaine Inc.

612-309-3527

Nick.Karos@universalibogaine.com

Related Links

https://universalibogaine.com

Copyright (c) 2025 TheNewswire - All rights reserved.